Sunitinib malate for the treatment of solid tumours: A review of current clinical data Journal Article
| Authors: | Motzer, R. J.; Hoosen, S.; Bello, C. L.; Christensen, J. G. |
| Article Title: | Sunitinib malate for the treatment of solid tumours: A review of current clinical data |
| Abstract: | Receptor tyrosine kinases (RTKs) play important roles in the regulation of cellular growth, and mutated or overexpressed RTKs have been implicated in various human cancers. Sunitinib malate is an oral multitargeted tyrosine kinase inhibitor with antitumour and antiangiogenic activity that recently received approval from the FDA for the treatment of advanced renal cell carcinoma and of gastrointestinal stromal tumours after disease progression on or intolerance to imatinib mesilate therapy. Sunitinib has also demonstrated promising clinical activity in the treatment of other advanced solid tumours. The present review provides an updated summary of emerging clinical experience with this promising new anticancer agent. © 2006 Informa UK Ltd. |
| Keywords: | clinical trial; drug tolerability; fatigue; neutropenia; review; cisplatin; doxorubicin; fluorouracil; placebo; sunitinib; advanced cancer; area under the curve; diarrhea; drug efficacy; drug potentiation; hypertension; nonhuman; solid tumor; antineoplastic agents; drug approval; antineoplastic agent; anorexia; neoplasms; animals; gastrointestinal stromal tumor; interleukin 2; melanoma; enzyme inhibition; anemia; blood toxicity; lung non small cell cancer; nausea; stomatitis; thrombocytopenia; vomiting; clinical protocol; antineoplastic activity; drug structure; inhibitor; protein tyrosine kinase; kidney carcinoma; lymphocytopenia; neuroendocrine tumor; sarcoma; disease model; gamma interferon; skin discoloration; thyroid cancer; octreotide; dermatitis; drug metabolism; ketoconazole; taxane derivative; drug half life; gist; indoles; pyrroles; solid tumours; drug dose regimen; hand foot syndrome; rifampicin; mouth pain; triacylglycerol lipase; drug elimination; hair discoloration; rcc; antiangiogenic; su11248; antitumour; multitargeted tyrosine kinase |
| Journal Title: | Expert Opinion on Investigational Drugs |
| Volume: | 15 |
| Issue: | 5 |
| ISSN: | 1354-3784 |
| Publisher: | Taylor & Francis Group |
| Date Published: | 2006-05-01 |
| Start Page: | 553 |
| End Page: | 561 |
| Language: | English |
| DOI: | 10.1517/13543784.15.5.553 |
| PUBMED: | 16634693 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 60" - "Export Date: 4 June 2012" - "CODEN: EOIDE" - "Source: Scopus" |
